Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MikeStockon Jun 03, 2021 1:12pm
128 Views
Post# 33319735

RE:RE:RE:Market knows

RE:RE:RE:Market knows
MrMugsy wrote:
Layth1990 wrote: The issue is management ,Just promises and vague statements! So much greed and everything they do they do fill their pokets with shares. Where is nassaq ? Where is phase 3 design and anticipated date ? Also, they are the champions of delays. They definitly don't have a concrete plan. I still remember dans words for no dilution at biohub, and we got diluted twice or more since. I an still hanging here for a hope, i will lose it and move forward one day. 


Check your calendar Layth ...

Since they are planning to go to P3 in the last three months of the year (best guess), you probably wont hear much about the P3 plan until late summer.

I recall NASDAQ being a later fall thing - but don't get too excited if the markets don't play nice.  I could see them move it out ... but I hope not.

I wouldn't exactly call AH a dilution - It's more of an acquisition.  We didn't use cash to make the purchase, we used shares.

None of that should be a surprise.

Not being critical of you - just putting things into perspective for everyone asking the same questions.

Cheers - Good Luck All.  (one step at a time and we'll get there).


Sure Mugs, but what I still don't understand, and even ATE never answered the question when I asked them, was why do the reverse split under the premise of an uplist and then wait a year. No institutions are buying now so the 40 cent price argument can't be made. I suspect that if we never did the split we wouldn't be stting at 39 cents today. 

<< Previous
Bullboard Posts
Next >>